Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D2C7-IT and 2141-V11 Combination Immunotherapy in Residual Disease for Adult Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma
NCT05734560Phase 2Recruiting
- Sponsor
- Istari Oncology
- Start
- Sep 2023
- Primary completion
- Oct 2026
- Modality
- scFv Fragments, Immunotoxins, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of D2C7-(scdsFv)-PE38KDEL, 2141-V11 in glioblastoma (GBM), sponsored by Istari Oncology. Started Sep 2023; status: recruiting.
02
Drugs
D2C7-(scdsFv)-PE38KDEL2141-V11
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05734560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05734560.